LMR Partners’s Titan Pharmaceuticals TTNP Stock Holding History

LMR Partners’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-15	Closed	-$105K	–	548
2017 Q2	$105K	Buy	+15	New	+$140K	0.01%	565

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's TTNP Position: Q3 2017 in Review

LMR Partners sold out of Titan Pharmaceuticals (TTNP) in Q3 2017, closing a stake of 15 shares — an estimated $105K sold.

LMR Partners first reported a position in TTNP in Q2 2017 and held it in 1 quarter. The position peaked at $105K in Q2 2017. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

LMR Partners reported no remaining Titan Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 15 Titan Pharmaceuticals shares in Q3 2017, an estimated $105K.
LMR Partners first reported a position in Titan Pharmaceuticals in Q2 2017 and held it in 1 quarter.
LMR Partners's Titan Pharmaceuticals position peaked at $105K in Q2 2017.
24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.